Evidence map›Paper›PMID 17287850›Full record

ArticleLeukemia2007

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

V H J van der Velden, G Cazzaniga, A Schrauder, J Hancock, P Bader, E R Panzer-Grumayer, T Flohr, R Sutton, H Cave, H O Madsen and 10 more

3 registry-linked trialsAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Leukemia, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 301 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
301citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02555969 completednot on this mapstarted 2015, after this paper: background citation

Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis

TypeobservationalSponsorTufts Medical CenterRan2015 to 2020Enrolled56ConditionsAmyloidosis, Primary Amyloidosis
NCT04554485 phase2completednot on this mapstarted 2019, after this paper: background citation

Single Cycle of Blinatumomab Followed by High-dose Chemotherapy in the Induction Therapy for Ph-negative Acute Lymphoblastic Leukemia in Adults

TypeinterventionalSponsorInstitute of Hematology and Blood Transfusion, Czech RepublicRan2019 to 2024Enrolled27ConditionsLymphoblastic Leukemia, Acute, Adult, Ph Negative ALL, Newly DiagnosedArmsBlinatumomab
NCT06845592 narecruitingnot on this mapstarted 2025, after this paper: background citation

SHARP - Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia

TypeinterventionalSponsorUniversity Of PerugiaRan2025 to 2031Enrolled51ConditionsAcute Myeloid Leukaemia (AML), Acute Lymphoblastic Leukemia ALL, High Risk Leukaemia, Leukaemia RelapseArmstotal marrow/lymphoid irradiation
3 · Its place in the literature

Who cites it

301 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Trial
  18. Trial
  19. Article
  20. Article

241 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

V H J van der VeldenDepartment of Immunology, Erasmus MC, Rotterdam, The Netherlands.
G Cazzaniga
A Schrauder
J Hancock
P Bader
E R Panzer-Grumayer
T Flohr
R Sutton
H Cave
H O Madsen
J M Cayuela
J Trka
C Eckert
L Foroni
U Zur Stadt
K Beldjord
T Raff
C E van der Schoot
J J M van Dongen
European Study Group on MRD detection in ALL (ESG-MRD-ALL)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the analysis of minimal residual disease (MRD). To ensure comparable MRD results between different MRD-polymerase chain reaction (PCR) laboratories, standardization and quality control are essential. The European Study Group on MRD detection in ALL (ESG-MRD-ALL), consisting of 30 MRD-PCR laboratories worldwide, has developed guidelines for the interpretation of real-time quantitative PCR-based MRD data. The application of these guidelines ensures identical interpretation of MRD data between different laboratories of the same MRD-based clinical protocol. Furthermore, the ESG-MRD-ALL guidelines will facilitate the comparison of MRD data obtained in different treatment protocols, including those with new drugs.

Indexed as

Gene RearrangementDNA, NeoplasmGenes, ImmunoglobulinHumansNeoplasm, ResidualPolymerase Chain ReactionPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Antigen, T-CellDNA, NeoplasmReceptors, Antigen, T-Cell

Identifiers

PMID17287850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.